A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis
NCT ID: NCT04614298
Last Updated: 2021-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2021-01-31
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
NCT02982005
A Phase 4 Clinical Study of Brodalumab
NCT04183881
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
NCT02786732
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
NCT05531682
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
NCT04305327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KHK4827 210 mg SC (Subcutaneous)
Single SC administration
KHK4827-Active
Single SC administration
Placebo SC
Single SC administration
KHK4827-Placebo
Single SC administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KHK4827-Active
Single SC administration
KHK4827-Placebo
Single SC administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those who have involved BSA (the percentage (%) of body surface area involved with lesion) ≥10%, PASI (Psoriasis Area and Severity Index) ≥12 and sPGA (static Physician's global assessment) ≥ 3 at screening and at baseline.
Exclusion Criteria
* Those who have skin conditions other than psoriasis including eczema at the time of the screening that would interfere with evaluations of the study drug.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyowa Kirin China Pharmaceutical Co., Ltd.
INDUSTRY
Kyowa Kirin Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 01
Beijing, , China
Site 03
Beijing, , China
Site 04
Beijing, , China
Site 10
Beijing, , China
Site 11
Beijing, , China
Site 12
Beijing, , China
Site 21
Beijing, , China
Site 07
Changchun, , China
Site 13
Changchun, , China
Site 14
Chongqing, , China
Site 09
Hangzhou, , China
Site 17
Hangzhou, , China
Site 24
Hangzhou, , China
Site 25
Nanjing, , China
Site 02
Shanghai, , China
Site 05
Shanghai, , China
Site 08
Shanghai, , China
Site 06
Tianjin, , China
Site 22
Tianjin, , China
Site 23
Ürümqi, , China
Site 16
Wenzhou, , China
Site 19
Wuhan, , China
Site 20
Wuhan, , China
Site 15
Xi'an, , China
Site 18
Xi'an, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4827-CN001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.